Wright claims US first for allograft bone graft pellets:
This article was originally published in Clinica
Executive Summary
The US FDA has given Wright Medical the go-ahead to market what promises to be an improved version of its Osteoset bone graft substitute. The Osteoset calcium sulfate pellets are now available in a form that contains human demineralised bone matrix (DBM) proteins. Osteoset with DBM have been shown to form natural bone architecture more rapidly than Osteoset calcium sulfate pellets alone, says the Arlington, Tennessee firm. Osteoset DBM joins Wright's Allomatrix putty - which received regulatory clearance in March - as the first FDA-cleared allograft-containing bone void fillers to become available in the US, the company claims.
You may also be interested in...
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.